Halozyme's revenue momentum is accelerating sharply, with 2026Q2 revenue up 47.7% year-over-year to $481.0M and gross margin expanding to 83.5%, driven by its asset-light royalty model and strong partner demand. Operating leverage is evident as operating margi...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 47.7% year-over-year in 2026Q2, with gross margin expanding to 83.5% and operating margin reaching 59.8%, though a one-time charge in 2025Q4 caused a net loss of $141.6M.
Halozyme Therapeutics, Inc. (HALO) stock is actively traded with vital information available for investors.
HALO stock provides real-time price data, charts, key statistics, and news for informed decisions.
MarketBeat offers HALO stock analysis, price targets, earnings estimates, and short interest data.
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $2.28+27.4% vs $1.79 | $481M+19.6% vs $402M |
Q2 2026 May 11, 2026 | $1.60+3.2% vs $1.55 | $377M+5.0% vs $359M |
Q1 2026 Feb 17, 2026 | -$0.24-111.2% vs $2.15 | $452M+3.7% vs $436M |
Q4 2025 Nov 3, 2025 | $1.72+5.5% vs $1.63 | $354M-20.7% vs $447M |
First Citizens Bank and Trust Co. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 59.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,617 shares of the biopharmaceutical company's stock after selling 5,312 shares during the quarter. First Citizens
HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.
ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Benchmark HALO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Halozyme Therapeutics, Inc. (HALO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $125.63 | $14.9B | 49.07 | 37.55% | 22.69% | 153.59% | — | |
| $224.03 | $29.91B | 96.15 | 65.19% | 16.82% | 93.61% | — | |
| $42.93 | $7.13B | -18.04 | 33.87% | -64.64% | -110.84% | — | |
| $58.02 | $8.17B | -4755.74 | 23258.15% | -47.79% | -60.05% | — | |
| $64.53 | $16.22B | 23.21 | 6.98% | 35.33% | 42.49% | — | |
| $20.66 | $1.52B | 6.26 | 18.52% | 80.56% | 30.03% | — |
Halozyme Therapeutics, Inc. (HALO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Halozyme Therapeutics, Inc. (HALO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 2, 2026·SEC
May 11, 2026·SEC
Get notified when HALO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Halozyme Therapeutics, Inc. (HALO) stock FAQ — growth, dividends, profitability & financials explained
Halozyme Therapeutics, Inc. (HALO) reported $1.66B in revenue for fiscal year 2025. This represents a 6739774% increase from $0.0M in 2001.
Halozyme Therapeutics, Inc. (HALO) grew revenue by 37.6% over the past year. This is strong growth.
Yes, Halozyme Therapeutics, Inc. (HALO) is profitable, generating $413.6M in net income for fiscal year 2025 (22.7% net margin).
Halozyme Therapeutics, Inc. (HALO) has a return on equity (ROE) of 153.6%. This is excellent, indicating efficient use of shareholder capital.
Halozyme Therapeutics, Inc. (HALO) generated $806.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
